SK Biopharm Signs 4.3 Billion KRW Pharmaceutical Supply Contract

[Asia Economy Reporter Lee Seon-ae] SK Biopharm announced on the 30th that it has signed a contract to supply pharmaceuticals worth 4,315,570,000 KRW by the end of next year. The contract is to supply finished pharmaceuticals and raw materials under the technology transfer agreement signed with Arvelle Therapeutics for the European sales of SK Biopharm's new epilepsy treatment drug Cenobamate. The contract amount corresponds to 16.60% of sales.